ArticleCancers2022

Event-Free Survival in Patients with Early HER2-Positive Breast Cancer with a Pathological Complete Response after HER2-Targeted Therapy: A Pooled Analysis.

Sandra M Swain et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.